论文部分内容阅读
目的评价血脂异常的非糖尿病病人给予阿托伐他汀治疗后血清脂联素的变化及对糖代谢的影响。方法 20例血脂异常的非糖尿病患者,给予阿托伐他汀20 mg.d-1,连服12周,于服药前、服药4周和12周时抽取空腹静脉血,分别测定空腹血糖、糖化血红蛋白、胰岛素、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、脂联素。结果用药4周后,患者总胆固醇、低密度脂蛋白胆固醇明显降低(P<0.05),高密度脂蛋白胆固醇明显升高(P<0.05),血清脂联素水平明显升高(P<0.05)。继续服药至12周,总胆固醇、低密度脂蛋白胆固醇进一步下降,所有患者均达到治疗目标,而血清脂联素无明显变化。治疗前后患者空腹血糖、糖化血红蛋白、胰岛素均无明显改变。结论阿托伐他汀治疗后可明显降低总胆固醇、低密度脂蛋白胆固醇,升高血清脂联素水平,对糖代谢无明显影响。
Objective To evaluate the changes of serum adiponectin and its effect on glucose metabolism in patients with nondiabetic dyslipidemia after atorvastatin treatment. Methods Twenty patients with non-diabetic dyslipidemia were given atorvastatin 20 mg.d-1 for 12 weeks. Fasting venous blood was taken before fasting, 4 weeks and 12 weeks after taking the drug. Fasting blood glucose, glycosylated hemoglobin , Insulin, Total Cholesterol, Triglycerides, LDL Cholesterol, HDL Cholesterol, Adiponectin. Results After 4 weeks of treatment, the levels of total cholesterol and low density lipoprotein cholesterol were significantly decreased (P <0.05), the levels of high density lipoprotein cholesterol (HDL - C) and adiponectin were significantly increased (P <0.05) . Continue to medication until 12 weeks, total cholesterol, low density lipoprotein cholesterol decreased further, all patients reached the goal of treatment, while no significant changes in serum adiponectin. Before and after treatment, fasting blood glucose, glycosylated hemoglobin, insulin had no significant change. Conclusion Atorvastatin treatment can significantly reduce total cholesterol, low density lipoprotein cholesterol, elevated serum adiponectin levels, no significant effect on glucose metabolism.